Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-13-1777
Full Text
Open PDFAbstract
Available in full text
Date
October 28, 2013
Authors
Publisher
American Association for Cancer Research (AACR)